Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 6/20 | 0.48 |
| ▸ | MMP3 | P08254 | 3/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | PNMT | P11086 | 6/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2084434 | 1.00 | MMP8 (0.48) | MMP8MMP3PTPN1AGTR2MAPT | |
| SCHEMBL6392086 | 0.85 | PTPN1 (0.63) | MMP8MMP3PTPN1AGTR2MAPT | |
| SCHEMBL8248218 | 0.83 | PNMT (0.46) | MMP8MMP3PNMTADRA2AADRA2B | |
| SCHEMBL7511373 | 0.83 | MMP8 (0.48) | MMP8MMP3PTPN1AGTR2MAPT | |
| SCHEMBL2084392 | 0.82 | PTPN1 (0.48) | MMP8MMP3PTPN1AGTR2PDE4B | |
| SCHEMBL2084395 | 0.82 | PTPN1 (0.48) | MMP8MMP3PTPN1AGTR2PDE4B | |
| Hydrochloric Acid SCHEMBL2083230 | 0.81 | PTPN1 (0.47) | MMP8MMP3PTPN1AGTR2PDE4B | |
| Hydrochloric Acid SCHEMBL2083227 | 0.81 | PTPN1 (0.47) | MMP8MMP3PTPN1AGTR2PDE4B | |
| SCHEMBL6390617 | 0.73 | PTPN1 (0.49) | MMP8MMP3PTPN1MAPTDRD2 | |
| SCHEMBL15621374 | 0.73 | PTPN1 (0.49) | MMP8MMP3PTPN1MAPTDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| EP-1835934-A2 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | MMP8 90/4885MMP3 589/4885PTPN1 153/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | MMP8 136/4885MMP3 638/4885PTPN1 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.